Skip to main content

Table 2 Univariate analysis of clinico-pathological prognostic markers associated with recurrence-free survival in patients with HCC.

From: Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma

  Nontumoral HCC Cohort (N = 44) Tumor HCC Cohort (N = 43)
  Risk ratio 95% CI P-value Risk ratio 95% CI P-value
Tumor stage 2.48 1.39-4.51 0.002 2.54 1.41-4.70 0.002
Tumor diameter 1.59 1.17-2.09 0.005 1.65 1.19-2.24 0.004
Number of tumors 2.41 1.17-4.68 0.02 2.10 0.99-4.19 0.05
Platelet count 0.95 0.87-1.03 0.22 0.97 0.89-1.06 0.53
Sex [male] 1.44 0.67-3.43 0.36 1.62 0.74-4.08 0.24
Indocyanine green 1.02 0.97-1.06 0.40 1.01 0.97-1.05 0.56
Prothrombin time 0.99 0.97-1.02 0.45 0.99 0.97-1.02 0.40
Portal vein invasion [present] 1.41 0.33-4.06 0.59 1.42 0.34-4.08 0.59
Liver resection procedure [lobular] 1.14 0.62-1.82 0.65 1.13 0.61-1.81 0.66
Total Bilirubin 1.26 0.42-3.24 0.66 1.35 0.50-3.19 0.54
Fibrosis score 0.96 0.65-1.49 0.86 0.92 0.63-1.38 0.67
Tumor differentiation [moderate-poor] 1.08 0.47-2.93 0.86 0.84 0.35-2.49 0.73
Age 1.00 0.96-1.05 0.90 1.02 0.97-1.07 0.53
Alanine aminotransferase 1.00 0.99-1.01 0.96 1.00 0.99-1.01 0.94
α-Fetoprotein 1.00 1.00-1.00 0.99 1.00 1.00-1.00 0.90
  1. Patients with HCV-associated HCC were divided into two cohorts based on the availability of mRNA samples. Univariate Cox proportional hazard model analysis was used to assess relative risk for each clinical variable. Relative risk >1 identifies shortened recurrence-free survival. Significant variables are highlighted in bold.